PTC Therapeutics (PTCT) Q3 Revenues Beat

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.89), $0.49 worse than the analyst estimate of ($1.40). Revenue for the quarter came in at $138.7 million versus the consensus estimate of $126.44 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q4 EPS by 16c, Offers Guidance
• Jefferies finds gaps in Australia's new climate disclosures
• Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance